1-(6-methoxypyridin-3-yl)cyclohexanol | 133806-34-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(6-methoxypyridin-3-yl)cyclohexanol
• 英文别名: 5-(1-hydroxycyclohexyl)-2-methoxypyridine；1-(6-methoxypyridin-3-yl)cyclohexan-1-ol
• CAS: 133806-34-5
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: RHEIKYJMTBXTJE-UHFFFAOYSA-N

物化性质

• 沸点：
  336.5±32.0 °C(predicted)
• 密度：
  1.130±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(6-methoxypyridin-3-yl)cyclohexanol 以89%的产率得到
  参考文献：
  名称：

  Firk David M., Ettland Richard C., Synth. Commun, 24 (1994) N 19, S 2793-2796

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲氧基吡啶 在 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 异丙基氯化镁 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 20.75h， 生成 1-(6-methoxypyridin-3-yl)cyclohexanol
  参考文献：
  名称：

  二丁基（异丙基）镁酸锂（1-）和氯化锂通过卤素-镁交换进行非低温合成功能化的2-甲氧基吡啶

  摘要：

  使用二丁基（异丙基）镁酸锂（1-）和相应的溴或碘类似物制备在3-，5-或6-位官能化的2-甲氧基吡啶和在3-位官能化的2,6-二甲氧基吡啶。非低温条件下的氯化锂。根据在两种镁酸盐之间的选择以及反应介质中氯化锂的存在与否，对程序进行了优化。 吡啶-镁-锂-有机金属试剂

  DOI：

  10.1055/s-0031-1289687

文献信息

• [EN] NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS<br/>[FR] NOUVEAUX DERIVES DE PYRIDINONE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTERIQUES POSITIFS DES RECEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006030032A1

  公开（公告）日：2006-03-23

  The present invention relates to novel compounds, in particular novel pyridinone derivat ives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subt ype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新化合物，特别是根据式（I）X R1 N Y（I）R2 R3定义的新吡啶酮衍生物。根据本发明的化合物是代谢型受体-亚型2（'mGluR2'）的阳性变构调节剂，对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体的mGluR2亚型的疾病具有用处。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统障碍组中选择的。该发明还涉及制备此类化合物和组合物的药物组合物和过程，以及利用这类化合物预防和治疗涉及mGluR2的这类疾病。
• 5-(1-aminocyclohexyl)-2(1H)-pyridinone compounds which have
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04978663A1

  公开（公告）日：1990-12-18

  There are described compounds of the formula ##STR1## where n is 1,2 or 3; R.sub.1 is hydrogen, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl, loweralkyl, arylloweralkyl, ##STR2## R.sub.5 and R.sub.6 being independently loweralkyl or alternatively the group ##STR3## taken as a whole is ##STR4## R.sub.2 is hydrogen, loweralkyl, loweralkenyl, arylloweralkyl, --CH.sub.2 C.tbd.CH, R.sub.7 and R.sub.8 being independently loweralkyl or alternatively the group ##STR5## taken as a whole is ##STR6## R.sub.3 is hydrogen or loweralkyl; and R.sub.4 is hydrogen or loweralkyl; which compounds are useful as analgesic agents and also for treating various memory dysfunctions.

  描述了公式##STR1##的化合物，其中n为1、2或3；R.sub.1是氢、甲酰基、低级烷基碳酰基、芳基低级烷基碳酰基、低级烷基、芳基低级烷基、##STR2##；R.sub.5和R.sub.6独立地为低级烷基，或者整个组##STR3##为##STR4##；R.sub.2是氢、低级烷基、低级烯基、芳基低级烷基、--CH.sub.2 C.tbd.CH，R.sub.7和R.sub.8独立地为低级烷基，或者整个组##STR5##为##STR6##；R.sub.3是氢或低级烷基；R.sub.4是氢或低级烷基；这些化合物作为镇痛剂是有用的，也用于治疗各种记忆功能障碍。
• 5-(1-hydroxylcycloalkyl)-2-methoxy pyridine compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05204480A1

  公开（公告）日：1993-04-20

  There are described compounds of the formula ##STR1## where n is 1, 2 or 3; R.sub.1 is hydrogen, formyl, loweralkylcarbonyl, arylloweralkylcarbonyl, loweralkyl, arylloweralkyl, ##STR2## R.sub.5 and R.sub.6 being independently loweralkyl or alternatively the group ##STR3## taken as a whole is ##STR4## R.sub.2 is hydrogen, loweralkyl, loweralkenyl, arylloweralkyl, --CH.sub.2 C.tbd.CH, ##STR5## R.sub.7 and R.sub.8 being independently loweralkyl or alternatively the group ##STR6## taken as a whole is ##STR7## R.sub.3 is hydrogen is loweralkyl; and R.sub.4 is hydrogen or loweralkyl; which compounds are useful as analgesic agents and also for treating various memory dysfunctions.

  描述了式子为##STR1##的化合物，其中n为1、2或3；R.sub.1为氢、甲酰、较低烷基羰基、芳基较低烷基羰基、较低烷基、芳基较低烷基、##STR2## R.sub.5和R.sub.6分别独立地为较低烷基或作为整体为##STR3##；R.sub.2为氢、较低烷基、较低烯基、芳基较低烷基、--CH.sub.2 C.tbd.CH、##STR5## R.sub.7和R.sub.8分别独立地为较低烷基或作为整体为##STR6##；R.sub.3为氢或较低烷基；R.sub.4为氢或较低烷基。这些化合物可用作镇痛剂，并且还可用于治疗各种记忆障碍。
• 5-(1-aminocyclohexyl)-2(1H)-pyridinone and related compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US05039809A1

  公开（公告）日：1991-08-13

  A compound of the formula: ##STR1## where n is 1, 2, or 3; R.sub.3 is hydrogen or loweralkyl; R.sub.4 is hydrogen or loweralkyl; and Ar is a phenyl group optionally mono-substituted with a loweralkoxy, halogen or trifluoromethyl group which are useful as intermediates.

  一种化合物的公式：##STR1## 其中n为1、2或3；R.sub.3为氢或低碳基；R.sub.4为氢或低碳基；Ar为苯基，可选择性地单取代于低碳氧基、卤素或三氟甲基基团，这些化合物是有用的中间体。
• NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS
  申请人：Imogai Julien Hassan

  公开号：US20070213323A1

  公开（公告）日：2007-09-13

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) X R1 N Y (I) R2 R3 wherein all radicals are defined in the application. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是按照公式（I）X R1 N Y（I）R2 R3定义的新型吡啶酮衍生物。该发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，适用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神障碍以及涉及代谢型受体亚型2的疾病。特别是，这些疾病是选择自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的一组。本发明还涉及制备这种化合物和组合物的制药组合物和制备过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病的用途。